Corporate News

New System Installation

18 September 2020

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary investigational drug-device combination diagnostic for magnetic resonance imaging (MRI), announces that it has completed the  installation of its latest research unit order for a 9820 Xenon Polariser system at the University of Kansas Medical Center ("KU Medical Center")

KU Medical Center is a major research and teaching hospital and this polariser will form the cornerstone of a new hyperpolarised 129Xe imaging research programme. Following this installation, the total number of the Company's polarisers installed is 23.

Mario Castro MD MPH Division Chief, Pulmonary, Critical Care and Sleep Medicine; Vice Chair for Clinical and Translational Research, Director of the Rainbow Clinical Trials Science Unit, Frontiers of KU Medical Center said: "We are excited to utilise the latest technology in lung imaging, hyperpolarised Xenon gas MRI, to evaluate and assess response to therapy in our patients with lung disease."

Richard Hullihen, CEO of Polarean, said: "We look forward to extending our working relationship with KU Medical Center as they launch their pulmonary research programmes, thereby expanding the clinical and public health frontiers of hyperpolarised xenon imaging to help clinicians and patients with lung diseases."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.


Polarean Imaging plc /
Richard Hullihen, Chief Executive Officer
Jonathan Allis, Chairman
Via Walbrook PR
SP Angel Corporate Finance LLPNomad and Broker Tel: +44 (0)20 3470 0470
David Hignell / Soltan Tagiev (Corporate Finance)  
Vadim Alexandre / Rob Rees (Corporate Broking)  
Walbrook PR Tel: +44 (0)20 7933 8780 or [email protected]
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893/ +44 (0)7876 741 001


About Polarean (

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

The Group also develops high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimise the imaging of 129Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.

Investor Alert

Sign up for Email Alerts